FEATURED COMPANIES
- Atomwise, Inc.
- Bioage
- Envisagenics
- Insilico Medicine
- Numerate
- Twoxar, Incorporated
Global Artificial Intelligence (AI) in Drug Discovery Market to Reach $2.9 Billion by 2027
Amid the COVID-19 crisis, the global market for Artificial Intelligence (AI) in Drug Discovery estimated at US$589.5 Million in the year 2020, is projected to reach a revised size of US$2.9 Billion by 2027, growing at a CAGR of 25.7% over the analysis period 2020-2027. Oncology, one of the segments analyzed in the report, is projected to record a 22.4% CAGR and reach US$722.9 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Neurodegenerative Diseases segment is readjusted to a revised 23.6% CAGR for the next 7-year period.
The U.S. Market is Estimated at $176.3 Million, While China is Forecast to Grow at 25.2% CAGR
The Artificial Intelligence (AI) in Drug Discovery market in the U.S. is estimated at US$176.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$511.4 Million by the year 2027 trailing a CAGR of 25.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 22.7% and 22.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 18.3% CAGR.
Metabolic Diseases Segment to Record 27.5% CAGR
In the global Metabolic Diseases segment, USA, Canada, Japan, China and Europe will drive the 27.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$87 Million in the year 2020 will reach a projected size of US$475.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$351.2 Million by the year 2027.
Select Competitors (Total 36 Featured):
Amid the COVID-19 crisis, the global market for Artificial Intelligence (AI) in Drug Discovery estimated at US$589.5 Million in the year 2020, is projected to reach a revised size of US$2.9 Billion by 2027, growing at a CAGR of 25.7% over the analysis period 2020-2027. Oncology, one of the segments analyzed in the report, is projected to record a 22.4% CAGR and reach US$722.9 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Neurodegenerative Diseases segment is readjusted to a revised 23.6% CAGR for the next 7-year period.
The U.S. Market is Estimated at $176.3 Million, While China is Forecast to Grow at 25.2% CAGR
The Artificial Intelligence (AI) in Drug Discovery market in the U.S. is estimated at US$176.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$511.4 Million by the year 2027 trailing a CAGR of 25.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 22.7% and 22.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 18.3% CAGR.
Metabolic Diseases Segment to Record 27.5% CAGR
In the global Metabolic Diseases segment, USA, Canada, Japan, China and Europe will drive the 27.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$87 Million in the year 2020 will reach a projected size of US$475.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$351.2 Million by the year 2027.
Select Competitors (Total 36 Featured):
- Atomwise, Inc.
- Benevolentai
- Berg LLC
- Bioage
- Cloud Pharmaceuticals, Inc.
- Cyclica
- Deep Genomics
- Envisagenics
- Exscientia
- Google (A Subsidiary of Alphabet Inc.)
- IBM Corporation
- Insilico Medicine
- Microsoft Corporation
- Numedii, Inc.
- Numerate
- NVIDIA Corporation
- Owkin, Inc.
- Twoxar, Incorporated
- Verge Genomics
- Xtalpi, Inc.
Frequently Asked Questions about the Global Market for Artificial Intelligence (AI) in Drug Discovery
What is the estimated value of the Global Market for Artificial Intelligence (AI) in Drug Discovery?
What is the growth rate of the Global Market for Artificial Intelligence (AI) in Drug Discovery?
What is the forecasted size of the Global Market for Artificial Intelligence (AI) in Drug Discovery?
Who are the key companies in the Global Market for Artificial Intelligence (AI) in Drug Discovery?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Atomwise, Inc.
- Bioage
- Envisagenics
- Insilico Medicine
- Numerate
- Twoxar, Incorporated
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
IV. COMPETITION
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Atomwise, Inc.
- Benevolentai
- Berg LLC
- Bioage
- Cloud Pharmaceuticals, Inc.
- Cyclica
- Deep Genomics
- Envisagenics
- Exscientia
- Google (A Subsidiary of Alphabet Inc.)
- IBM Corporation
- Insilico Medicine
- Microsoft Corporation
- Numedii, Inc.
- Numerate
- NVIDIA Corporation
- Owkin, Inc.
- Twoxar, Incorporated
- Verge Genomics
- Xtalpi, Inc.
Note: Product cover images may vary from those shown
